AMRX vs PATH
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AMRX and PATH stock pages for the full models.
Not investment advice.